CRISPR Therapeutics Aktie
43,20
EUR
-0,60
EUR
-1,37
%
49,52
USD
-2,69
USD
-5,15
%
Werbung
CRISPR Therapeutics Aktie Analyse
| 26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
| 30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
| 15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
| 28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
| 14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung
Werbung